CompletedNot Applicable

GliomaAI-Oligo: MRI-Based Detection of IDH Mutant Oligodendroglioma

India1,372 participantsStarted 2017-03-14

Plain-language summary

The goal of this observational study is to learn whether an artificial intelligence system called GliomaAI-Oligo can help detect a specific molecular type of brain tumour called Oligodendroglioma using routine MRI scans. The study uses previously collected and fully anonymised MRI data from 1,372 patients from 13 institutions in the Cancer Imaging Archive (TCIA). The main questions it aims to answer are: * How accurately can GliomaAI-Oligo identify Oligodendroglioma from MRI scans? * How well does the system perform across data from different hospitals and patient groups? Researchers will use existing MRI scans and clinical information to train and test the AI system. No new scans, treatments, or hospital visits are required for participants, and all data used is fully anonymised and obtained from an existing research database. Participants will not be asked to do anything, as this study only uses previously collected imaging data.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult (\>=18 years of age) * Having pre op MRI scan * Having biopsy / surgery * Having post biopsy/ surgery histology diagnosis and genetic analysis. Exclusion Criteria: * MRI scan significantly degraded by motion or other artefact * Incomplete genetic analysis * Prior treatment (e.g., radiotherapy or chemotherapy) before baseline MRI

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Diagnostic performance of GliomaAI-Oligo for identification of IDH mutant Oligodendroglioma from MRI, measured by accuracy, sensitivity, specificity, positive predictive value, negative predictive value, and area under the ROC

Timeframe: Perioperative

Trial details

NCT IDNCT07673705

SponsorDeep Learning Institute of Radiological Sciences

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-03-09

View on ClinicalTrials.gov More Glioma trials